
Conference Coverage
Latest News

Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows

Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis

Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo

Honoring World Stroke Day: Insights on Systemic Stroke Risk and Prevention Strategies

Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials

Shorts










Videos
Podcasts
Continuing Medical Education
All News

Obexelimab shows promising results in reducing lesions in relapsing multiple sclerosis, highlighting its potential as a new treatment for autoimmune diseases.

Amid World Stroke Day, neurosurgeon Evan Luther, MD, discussed the PICASSO trial’s effort to clarify the role of acute carotid stenting during mechanical thrombectomy for tandem occlusions in ischemic stroke.

An analysis of the first 110 patients screened for the ARISE study showed that an independent adjudication committee confirmed the diagnosis of CIDP in nearly 3-quarters of cases.

The chief science officer at the American Heart Association discusses its priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day 2025.

A post-hoc analysis study revealed apomorphine sublingual film was efficacious over a long term period across various age ranges, including elders, with Parkinson disease.

The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.

Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
Exenatide shows effects on brain metabolism in Parkinson disease but fails to provide clinical benefits, as recent trials reveal mixed results.

Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure during pregnancy and lactation in women with MS.

Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.

Paraneoplastic Neurologic Syndromes Present Before Testicular Germ Cell Tumor Diagnosis, Study Shows
In a recent study of patients with testicular germ cell tumors, most exhibited paraneoplastic neurologic syndromes proceeding with their cancer diagnosis, often associated with specific neural autoantibodies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on genetics for epilepsy.

A recent study highlights the increased mortality risk linked to benzodiazepine and antipsychotic use in hospice patients with dementia, urging new prescribing guidelines.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 24, 2025.























































